Vaccines, drugs and diagnostics – All the main ammunition to fight a raging pandemic – will be in the spotlight in 2022.
In addition, acceleration in digital transformation, health innovation, telemedicine and focus on preventive care will also be the core theme.
This rate of change will accelerate up to 2022 as e-pharmacies, telemedicine, video consultation, can be used, and virtual care that witnesses large growth, bring savings & comfort for consumers.
This sector will continue to become hot red, with the simultaneously private equity agreement expected in active pharmaceutical transactions (raw materials) and formulations, while Medtech, health and diagnostic technology will be pursued by startup and investors, said PEWC India & Pharmacy Leader Sujay Shetty.
Analysts say this trend will continue to drive R & D, investment and value creation, with the domestic pharmaceutical market expected to touch $ 130 billion by 2030 – almost three times the growth of $ 45 billion this year.
Secretary of India Pharmacy Alliance General Sudarshan Jain said, “Covid is the biggest humanitarian challenge facing the world today.
This has brought the stage of the health care center and also the role of global cooperation and coordination.
The integrated approach to vaccine, therapeutic, testing and behavior In accordance with Covid it will be very important to fulfill this challenge.
“With the threat of mutant strains arising, the focus will be more and more people who are vaccinated, and to overcome the injustice of large vaccines globally.
It presents opportunities for contracting, R & D and innovation for domestic companies.
Pandemics have created unprecedented disorders in health ecosystems, highlighting urgency to increase health service infrastructure, and find partnerships and innovation spur.
Because health innovation is set to accelerate, this industry tends to be more personalized, more focused on preventive and more digital treatments.
Wearing, telemedicine and editing genes is another area that can attract investment.
“Since 2020, we have seen the SARS-COV-2 virus through various mutations and still pose a threat to the health and safety of people around the world.
Some mutations as we see in the omicron variant can cause re-infection of those who have been infected or in Some cases, even breakthrough infections.
Omicron, labeled as ‘variants of concern’ by WHO, has caused waves in cases throughout the world.
So, the threat is still a weaving of large and public health action needs to be continued.
Indian Pharmaceutical Industry and Brotherhood Health in general, which has played an important role so far, will continue to lead the fight.
From vaccines to develop drugs, supply all possible resources and essential drugs to fight pandemics, the industry has the ability to fight challenges in front, “Zydus said Cadila Managing Director of Patel Sharvil Patel.